Parkinson's disease.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D001545:Benserazide / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy; D011725:Pyridines / Q000506:poisoning; D051381:Rats
D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D011725:Pyridines; D007980:Levodopa; D001545:Benserazide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000547:Amantadine; D002230:Carbidopa